MedTrace Logo

Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's

NCT05491902 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2022-08-08

No results posted yet for this study

Summary

Measuring the rate of cerebral protein synthesis (rCPS) may enable us to better-understand the progression of Alzheimer's Disease (AD). This study is using a new method of measuring rCPS non-invasively, and to offer new approaches to the assessment of new therapeutic strategies in clinical trials.

Previous studies have established the utility of \[11C\]-Leucine PET to assess the rCPS. This study will use \[11C\]- Leucine PET to measure rCPS in AD patients versus age-matched and young healthy subjects to determine whether a measurable difference exists.

The study will involve participants receiving up to two PET scans, a structural MRI scan. The PET scanning procedures will involve some withdrawal of blood samples.

The ultimate goal of this proposal is to indicate new routes for treatment of AD.

Conditions

  • Alzheimer Disease

Interventions

DIAGNOSTIC_TEST

[C11] Leucine PET scan

Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.

DIAGNOSTIC_TEST

[18F] Flutemetamol PET scan

Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.

DIAGNOSTIC_TEST

MRI scan

Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Manchester

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2020-10-15
Completion
2020-10-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491902 on ClinicalTrials.gov